Fate Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Fate Therapeutics Inc FATE.OQ reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -46 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 43 cents per share. Wall Street expected results to range from -66 cents to -37 cents per share.

• Revenue rose 58.1% to $3.07 million from a year ago; analysts expected $1.33 million.

• Fate Therapeutics Inc's reported EPS for the quarter was a loss of 40 cents​.

• The company reported a quarterly loss of $47.68 million.

• Fate Therapeutics Inc shares had fallen by 26.9% this quarter and lost 31.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy," 11 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Fate Therapeutics Inc is $5.50

This summary was machine generated from LSEG data November 12 at 11:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)